Drugs / Pegtomarginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04136834 | Apr 2021 → Dec 2022 | high grade malignant neoplasm | Athenex, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegtomarginase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04136834 ↗ |
| Known as | PT01 | “PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing.” NCT04136834 ↗ |
| Route | Intravenous | “PT01 administered IV” NCT04136834 ↗ |